Drug intelligence / Profile preview

BIO-107

Development stage: Preclinical
Lead developer: BiOneCure Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

BIO-107 is an antibody-drug conjugate (ADC) being developed by BiOneCure Therapeutics for the treatment of acute myeloid leukemia (AML). Currently in the preclinical or lead development stage, BIO-107 is designed to selectively target AML cells and deliver a cytotoxic payload to induce cell death. While the specific target antigen and the chemical nature of the payload have not been publicly disclosed, the drug is part of BiOneCure's pipeline of innovative ADCs that leverage proprietary payload and linker technologies. The development of BIO-107 is led by a team of industry veterans with significant experience in ADC development from major pharmaceutical companies such as Pfizer and AstraZeneca.

Beyond the preview

Go deeper on BIO-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO-107.

Explore the full profile